Ownership

Who owns Contineum Therapeutics, Inc., from the filings themselves: stakes over 5% (Schedule 13D/G), the institutional managers reporting the stock each quarter (13F), and the funds holding it (N-PORT).

Stakes over 5%

Investors crossing 5% ownership must disclose it. Schedule 13G filers certify the stake is passive; Schedule 13D is the general form for everyone else — founders, strategic holders, and activists alike. Each entry is the holder's most recent disclosure. Coverage begins with SEC's structured filings from December 18, 2024; a holder appears once they file or amend after that date.

BALYASNY ASSET MANAGEMENT L.P., BAM GP LLC, Balyasny Asset Management Holdings LP August 14, 2026

BALYASNY ASSET MANAGEMENT L.P.: 7.1% · 2,335,550 shares — BAM GP LLC: 7.1% · 2,335,550 shares — Balyasny Asset Management Holdings LP: 7.1% · 2,335,550 shares

View filing (SCHEDULE 13G/A) Amendment #1

BlackRock, Inc. July 27, 2026

BlackRock, Inc.: 6.3% · 2,049,493 shares

View filing (SCHEDULE 13G)

6 more 5% stakes behind a free account

See every investor who has disclosed crossing 5% of Contineum Therapeutics, Inc..

Super investors holding CTNM

Every institutional manager whose latest 13F reports this stock, largest position first. "% of their portfolio" is the weight inside that manager's own book — how much conviction the position represents; "% of company" is how much of Contineum Therapeutics, Inc. they hold. Together these 127 managers report 105.55% of shares outstanding.

Investor	Position value	Shares	% of their portfolio	% of company	As of
MONTANOVA CAPITAL, LLC	$46.6M	2,841,334	0.85%	7.58%	June 30, 2026
Jupiter Topco LLC	$44.8M	2,734,836	0.02%	7.30%	June 30, 2026

125 more institutional holders behind a free account

See every manager reporting Contineum Therapeutics, Inc., how much of the company they hold, and how big the position is inside their own portfolio.

Funds holding CTNM

Funds disclosing this stock in their monthly N-PORT portfolio, with the position's share of the fund's net assets. Together these 68 funds hold 10.01% of shares outstanding — counted inside the manager totals above, not on top of them, since a fund's shares also appear in its manager's 13F.

Fund	Position value	% of net assets	% of company	As of
VANGUARD TOTAL STOCK MARKET INDEX FUND	$16.1M	0.00%	2.62%	June 30, 2026
Franklin Biotechnology Discovery Fund	$8.67M	0.84%	1.80%	April 30, 2026

66 more funds behind a free account

See every fund holding Contineum Therapeutics, Inc. and what share of its net assets the position represents.